Chris Raymond
Stock Analyst at Raymond James
(2.91)
# 1,448
Out of 5,131 analysts
9
Total ratings
66.67%
Success rate
46.88%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $63.00 | +95.24% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $39.25 | +14.65% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $29.31 | +19.41% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $105.05 | -0.05% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $9.78 | +135.17% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $35.35 | -15.13% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $11.11 | +575.07% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $63.00
Upside: +95.24%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $39.25
Upside: +14.65%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $29.31
Upside: +19.41%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $105.05
Upside: -0.05%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $9.78
Upside: +135.17%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $35.35
Upside: -15.13%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $11.11
Upside: +575.07%